申请人:Pierre Fabre Medicament
公开号:US06011032A1
公开(公告)日:2000-01-04
Substituted N-heterocyclyl-1-aryloxyalkyl-4-piperldineamines of formula (I) ##STR1## wherein each of R.sub.1 to R.sub.4, which are the same or different, is hydrogen, optionally branched C.sub.1-4 alkyl, optionally branched C.sub.1-4 alkyloxy, halo, nitro, hydroxy, or trifluoromethyl or trifluoromethoxyl; R.sub.5 is hydrogen, optionally branched C.sub.1-6 alkyl, optionally branched C.sub.7-12 phenylalkyl optionally substituted on the phenyl by one or more radicals having the same definition as R.sub.1 ; W and X are oxygen or sulphur; Y is C.sub.2-6 polymethylene or --CH.sub.2 --CH(OH)--CH.sub.2 --; and n is 0 or 1; and pure R or S isomers of said compounds, where applicable, as well as mixtures thereof, as well as therapeutically-acceptable organic or inorganic salts and hydrates of the compounds and a method for preparing the compounds and their use as drugs are all disclosed.
化学式(I)中的N-杂环基-1-芳氧基烷基-4-哌啶胺衍生物,其中R.sub.1到R.sub.4中的每个,它们相同或不同,是氢、可选择性支链的C.sub.1-4烷基、可选择性支链的C.sub.1-4烷氧基、卤素、硝基、羟基、三氟甲基或三氟甲氧基;R.sub.5是氢、可选择性支链的C.sub.1-6烷基、可选择性支链的C.sub.7-12苯基烷基,可选择性在苯基上用一个或多个具有与R.sub.1相同定义的基团取代;W和X是氧或硫;Y是C.sub.2-6聚亚甲基或--CH.sub.2--CH(OH)--CH.sub.2--;n为0或1;以及所述化合物的纯R或S异构体(如适用),以及它们的混合物,以及所述化合物的治疗上可接受的有机或无机盐和水合物,以及制备所述化合物的方法和它们作为药物的用途均已披露。